3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
10
Unknown
6
Not yet recruiting
4
Completed
4
Active not recruiting
2
Withdrawn
1
Terminated
1
Suspended
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
12
Myelodysplastic Syndromes
4
Neoplasm Metastasis
3
Melanoma
3
Leukemia, Myelomonocytic, Chronic
3
Breast Neoplasms
3
Advanced Solid Tumor
3
Recurrence
2
Ovarian Neoplasms
2
Lymphoma, B-Cell
2
Leukemia, Monocytic, Acute
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Papillomavirus Infections
1
Non-Squamous Non-small Cell Lung Cancer
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Multiple Myeloma
1
Microsatellite Instability
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Basophilic, Acute
1
Leukemia
1
Interventions
Carboplatin
85
pembrolizumab
78
Pemetrexed
68
Cisplatin
56
Paclitaxel
45
osimertinib
41
Nivolumab
40
durvalumab
37
Docetaxel
33
atezolizumab
20
Gemcitabine
18
Radiotherapy
17
Radiosurgery
16
amivantamab
15
Ipilimumab
15
130-nm albumin-bound paclitaxel
14
Taxes
13
Specimen Handling
12
Magnetic Resonance Spectroscopy
12
Crizotinib
11
lazertinib
9
Radiation
9
Immunoglobulin G
9
Drug Therapy
9
Disulfides
9
Bevacizumab
9
tislelizumab
8
cemiplimab
8
alectinib
8
Erlotinib Hydrochloride
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Non-Small-Cell Lung
×
Injections
×
Clear all
NCT05816252
2026-01-27
MK-2870-003
Klus Pharma Inc.
Phase 2
Active not recruiting
356 enrolled
NCT05688280
2025-01-08
INJECTABL-1
Immunophotonics, Inc.
Phase 1/2
Active not recruiting
42 enrolled